Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/25/15 | 8-K | Current report filing |
|
22 | |
| 08/21/15 | 8-K | Current report filing |
|
8 | |
| 08/20/15 | 8-K | Current report filing |
|
8 | |
| 08/18/15 | 8-K | Current report filing |
|
4 | |
| 08/17/15 | 8-K | Current report filing |
|
13 | |
| 08/14/15 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
52 |
| 08/13/15 | 8-K | Current report filing |
|
4 | |
| 08/06/15 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
6 | |
| 08/06/15 | DEF 14A | Definitive proxy statements |
|
25 | |
| 08/05/15 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
